Caris Life Sciences to Present Six Studies at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy CAI?
Source: PRnewswire
- Research Presentation: Caris Life Sciences will showcase six studies at the 2026 American Association for Cancer Research Annual Meeting, leveraging its multimodal database that integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and clinical data to advance precision oncology and enhance patient treatment outcomes.
- Multimodal Data Utilization: The studies focus on breast, prostate, lung, and colorectal cancers, revealing clinically relevant patterns through deep molecular analysis, demonstrating the transformative potential of multimodal molecular data to accelerate discovery and improve patient outcomes.
- Strengthened Collaborative Network: The collaboration with leading cancer centers underscores the power of large-scale real-world molecular evidence, enhancing the credibility of the research and providing critical clinical insights for future treatment decisions.
- Commitment to Technological Innovation: Caris is dedicated to developing innovative precision medicine solutions through advanced AI and machine learning technologies, showcasing its leadership in transforming healthcare and further solidifying its competitive advantage in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.790
Low
30.00
Averages
36.17
High
40.00
Current: 19.790
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Schedule: Caris Life Sciences will present at the BofA Securities Healthcare Conference in Las Vegas on May 12, 2026, from 10:00 to 10:30 AM PT, showcasing its latest advancements in precision medicine.
- Global Healthcare Conference: Additionally, Caris will speak at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026, from 10:40 to 11:15 AM ET, further enhancing its industry influence.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, driving transformation in early detection and therapy selection, thereby demonstrating its leadership in the health tech sector.
- Global Presence: With services offered in the U.S. and international markets, and offices in locations such as Tokyo, Japan, and Basel, Switzerland, Caris emphasizes its global strategy and commitment to international markets.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Participation: Caris Life Sciences will participate in the BofA Securities Healthcare Conference from May 12-14, 2026, in Las Vegas, and the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami, showcasing its advancements in precision medicine.
- Presentation Schedule: At the BofA conference, Caris will present on May 12 from 10:00 to 10:30 AM PT, and at the Goldman Sachs conference, the presentation is scheduled for June 8 from 10:40 to 11:15 AM ET, which is expected to attract attention from investors and industry experts.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, aiming to improve early disease detection and treatment options, thereby transforming the healthcare industry.
- Global Presence: With offices in Texas, Arizona, New York, Cambridge, Tokyo, and Basel, Caris provides services in the U.S. and international markets, demonstrating its strategic intent to expand in the global precision medicine market.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, aiming to enhance transparency and investor confidence through a live webcast discussing key financial metrics.
- Webcast Details: The earnings call is scheduled for 3:30 p.m. CT (4:30 p.m. ET), with a live link provided to ensure investors can access the latest company updates in real-time.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on innovative precision medicine solutions, committed to transforming healthcare through comprehensive molecular profiling.
- Technological Edge: The company leverages advanced AI and machine learning to create a large-scale clinico-genomic database, supporting the development of precision medicine diagnostic solutions that enhance early detection and therapy selection capabilities.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Collaborative Research Enhancement: UCSF's participation will deepen collaborative research with Caris POA members, leveraging Caris' AI-driven platform and multimodal database to improve clinical outcomes for cancer patients and advance personalized therapies.
- Data Resource Sharing: Caris POA members will gain access to one of the industry's largest multimodal databases, containing billions of data points, which will help prioritize therapeutic options and identify beneficial clinical trial opportunities, enhancing patient treatment outcomes.
- Precision Medicine Outlook: As an NCI-designated cancer center, UCSF's scientific discoveries and patient-centered cancer care will provide robust support for Caris' mission, driving breakthroughs in cancer detection, treatment, and survivorship.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Scientific Discovery Enhancement: UCSF's participation will bolster the alliance's scientific discovery capabilities, enhancing clinical outcomes for cancer patients through shared advanced molecular insights, highlighting the significance of precision medicine in cancer care.
- Data-Driven Innovation: Caris leverages its advanced AI-driven platform and extensive multimodal database to support alliance members in prioritizing therapeutic options and identifying clinical trial opportunities, thereby advancing personalized patient care.
- Commitment to Equity and Innovation: As an NCI-designated cancer center, UCSF is dedicated to accelerating breakthroughs in cancer detection, treatment, and survivorship by integrating laboratory discoveries with clinical trials, demonstrating a strong commitment to scientific excellence and patient care.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Schedule: Caris Life Sciences will present at the BofA Securities Healthcare Conference in Las Vegas on May 12, 2026, from 10:00 to 10:30 AM PT, showcasing its latest advancements in precision medicine.
- Global Healthcare Conference: Additionally, Caris will speak at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026, from 10:40 to 11:15 AM ET, further enhancing its industry influence.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, driving transformation in early detection and therapy selection, thereby demonstrating its leadership in the health tech sector.
- Global Presence: With services offered in the U.S. and international markets, and offices in locations such as Tokyo, Japan, and Basel, Switzerland, Caris emphasizes its global strategy and commitment to international markets.
See More
Caris Life Sciences to Present at Two Major Healthcare Conferences
- Conference Participation: Caris Life Sciences will participate in the BofA Securities Healthcare Conference from May 12-14, 2026, in Las Vegas, and the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami, showcasing its advancements in precision medicine.
- Presentation Schedule: At the BofA conference, Caris will present on May 12 from 10:00 to 10:30 AM PT, and at the Goldman Sachs conference, the presentation is scheduled for June 8 from 10:40 to 11:15 AM ET, which is expected to attract attention from investors and industry experts.
- Technological Innovation: Caris is committed to developing precision medicine solutions through comprehensive molecular profiling and advanced AI technologies, aiming to improve early disease detection and treatment options, thereby transforming the healthcare industry.
- Global Presence: With offices in Texas, Arizona, New York, Cambridge, Tokyo, and Basel, Caris provides services in the U.S. and international markets, demonstrating its strategic intent to expand in the global precision medicine market.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, aiming to enhance transparency and investor confidence through a live webcast discussing key financial metrics.
- Webcast Details: The earnings call is scheduled for 3:30 p.m. CT (4:30 p.m. ET), with a live link provided to ensure investors can access the latest company updates in real-time.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on innovative precision medicine solutions, committed to transforming healthcare through comprehensive molecular profiling.
- Technological Edge: The company leverages advanced AI and machine learning to create a large-scale clinico-genomic database, supporting the development of precision medicine diagnostic solutions that enhance early detection and therapy selection capabilities.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Collaborative Research Enhancement: UCSF's participation will deepen collaborative research with Caris POA members, leveraging Caris' AI-driven platform and multimodal database to improve clinical outcomes for cancer patients and advance personalized therapies.
- Data Resource Sharing: Caris POA members will gain access to one of the industry's largest multimodal databases, containing billions of data points, which will help prioritize therapeutic options and identify beneficial clinical trial opportunities, enhancing patient treatment outcomes.
- Precision Medicine Outlook: As an NCI-designated cancer center, UCSF's scientific discoveries and patient-centered cancer care will provide robust support for Caris' mission, driving breakthroughs in cancer detection, treatment, and survivorship.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Scientific Discovery Enhancement: UCSF's participation will bolster the alliance's scientific discovery capabilities, enhancing clinical outcomes for cancer patients through shared advanced molecular insights, highlighting the significance of precision medicine in cancer care.
- Data-Driven Innovation: Caris leverages its advanced AI-driven platform and extensive multimodal database to support alliance members in prioritizing therapeutic options and identifying clinical trial opportunities, thereby advancing personalized patient care.
- Commitment to Equity and Innovation: As an NCI-designated cancer center, UCSF is dedicated to accelerating breakthroughs in cancer detection, treatment, and survivorship by integrating laboratory discoveries with clinical trials, demonstrating a strong commitment to scientific excellence and patient care.
See More
